-
Physicians' preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in Chin
Author: Li, Yan; Du, Junni; Tian, Chenhui; Ma, Aixia; Tao, Tiantian; Chen, Pingyu
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2650162
-
Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cance
Author: Kou, Conghui; Wu, Huina; Liu, Lihui; Zhao, Xifeng; Nie, Jing
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2626573
-
Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cance
Author: Liu, Tong; Yao, Yao; Liu, Bingjie; Teng, Xue; Dong, Mei; Zhang, Xin
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2509706
-
Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the US
Author: Liu, Tong; Yao, Yao; Teng, Xue; Tong, Zhiqiang; Dong, Mei; Yao, Ruihong
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2521444
-
Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12
Author: Yao, Ruihong; Yao, Yao; Teng, Xue; Jin, Yao; Guan, Shangwei; Dong, Mei; Liu, Tong
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2521439
-
Cost-effectiveness analysis of Risdiplam and Nusinersen for the treatment of Chinese patients with spinal muscular atroph
Author: Huang, Yueyang; Yuan, Hongmei; Huang, Zhe
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2499720
-
Impact of moderate and severe exacerbations on clinical prognosis and economic burden of chronic obstructive pulmonary disease in Chin
Author: Gan, Lei; He, Xiaoning; Wu, Jing
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2507425
-
Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in Chin
Author: Zhao, Shan; Kang, Shuo
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2483423
